子宫切除术对卵巢交界性肿瘤患者肿瘤学结局的影响:系统评价与Meta分析
该系统评价与Meta分析纳入12项研究共2223例卵巢交界性肿瘤患者,比较子宫切除术组与未行子宫切除术组的复发和死亡风险。子宫切除术组复发OR为0.23(p=0.00001),因BOT死亡OR为1.26(p=0.77),全因死亡OR为4.23(p=0.11)。作者认为保留子宫手术可能被推荐用于所有BOT患者,因其似乎增加复发风险,但不增加因病死亡或全因死亡风险。
要点
- 子宫切除术组较未行子宫切除术组复发风险降低,OR 0.23(p=0.00001)。
- 因BOT死亡OR 1.26(p=0.77),全因死亡OR 4.23(p=0.11),均未达统计学显著。
- 作者认为保留子宫手术可能被推荐用于所有BOT患者。
核心结论
- 作者认为保留子宫手术可能被推荐用于所有BOT患者,因其似乎增加复发风险,但不增加因病死亡或全因死亡风险。
研究设计与样本
- 系统评价与Meta分析,检索5个电子数据库自建库至2021年4月,纳入所有比较子宫切除术与未行子宫切除术治疗BOT的同行评议回顾性或前瞻性研究。
- 共纳入12项研究,评估2223例患者。
主要发现
- 与未行子宫切除术组相比,子宫切除术组复发OR为0.23(p=0.00001)。
- 与未行子宫切除术组相比,子宫切除术组因BOT死亡OR为1.26(p=0.77)。
- 与未行子宫切除术组相比,子宫切除术组全因死亡OR为4.23(p=0.11)。
- 亚组分析中,与未行子宫切除术组相比,子宫切除术组复发OR在浆液性亚组为0.21(p=0.003),在黏液性亚组为0.46(p=0.18),在FIGO I期亚组为0.23(p=0.0006),在FIGO II-III期亚组为0.29(p=0.04)。
临床怎么用
- 作者认为保留子宫手术可能被推荐用于所有BOT患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical management of Borderline ovarian tumors (BOT) can range from unilateral cystectomy to a more extensive surgical staging. However, the role of hysterectomy within the surgical staging is still debated. AIM: To assess the impact of hysterectomy on survival outcomes in BOT patients. MATERIALS AND METHODS: 5 electronic databases were searched from their inception to April 2021 for all peer-reviewed, retrospective or prospective studies, which compared treatment including hysterectomy versus treatment not including hysterectomy for BOT, in terms of recurrence and/or death. Pooled odds ratios (OR) with 95% confidence interval for recurrence, death due to BOT and death of any cause were calculated comparing hysterectomy group versus no hysterectomy group. Subgroup analyses for recurrence were based on BOT histotype (mucinous and serous) and FIGO stage (I and II-III). RESULTS: Twelve studies assessing 2223 patients were included. Compared to no hysterectomy group, hysterectomy group showed an OR of 0.23 (p = 0.00001) for recurrence, 1.26 (p = 0.77) for death due to BOT and 4.23 (p = 0.11) for death of any cause. At subgroup analyses, compared to no hysterectomy group, hysterectomy group showed an OR for recurrence of 0.21 (p = 0.003) in serous subgroup, of 0.46 (p = 0.18) in mucinous subgroup, of 0.23 (p = 0.0006) in FIGO stage I subgroup, and of 0.29 (p = 0.04) in FIGO stage II-III subgroup. CONCLUSIONS: Uterine-sparing surgery might be recommended in all BOT patients since it seems to increase the risk of recurrence, but not those of death due to disease or death of any cause.
引用
- Raimondo D, Raffone A, Zakhari A, et al. The impact of hysterectomy on oncological outcomes in patients with borderline ovarian tumors: A systematic review and meta-analysis. Gynecol Oncol. 2022. PMID: 35090745. doi:10.1016/j.ygyno.2022.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。